Single Nucleotide Polymorphism in Prolactin Gene Is Associated With Clinical Aggressiveness and Outcome of Canine Mammary Malignant Tumors

Abstract

Prolactin (PRL) is a key hormone involved in canine mammary development and tumorigenesis. In this study, the influence of a single nucleotide polymorphism (SNP) in the PRL gene (rs23932236) on the clinicopathological parameters and survival of dogs with canine mammary tumors (CMTs) was investigated. A total of 206 female dogs with spontaneous mammary tumors were enrolled in this study and circulating blood cells were genotyped. This specific SNP was associated with larger size (>3 cm diameter) for malignant tumors (P = .036), tumors with infiltrative/invasive growth pattern (P = .010), vascular invasion (P = .006), and lymph node metastasis (P = .004). Carriers of the variant allele had a shorter overall survival compared to the wild-type population with an overall survival of 18.7 months and 22.7 months, respectively (P = .004). These findings suggest that SNP rs23932236 of canine PRL gene may be used as an indicator for the development of clinically aggressive forms of CMTs.

Keywords

canine mammary tumors PRL gene SNP vascular invasion metastasis survival

Prolactin (PRL) is a polypeptide hormone synthesized mainly by the anterior pituitary gland and, in some species, also at extrapituitary sites including the mammary epithelium, placenta, uterus, bone, and lymphocytes.²⁵ This protein is recognized as a regulator of mammary development and lactation, being detected in epithelial cells of the lactating mammary gland as well as in the milk secretion.⁵⁹ PRL is also involved in other biological processes including reproduction, behavior, growth and development, immunity, and metabolism.^2,4

Various studies have demonstrated the proliferative, anti-apoptotic, and angiogenic effects of PRL in human breast epithelium, also pointing to a presumptive pro-carcinogenic action.^{1,17,48,54,60
–62} In fact, PRL serum levels have been correlated with human breast cancer development,^{17,23,27,50,58} and some authors reported higher PRL and/or PRL receptor expression in malignant tumors than in adjacent normal mammary tissue.^{36,44,49,54,63} Additional, genetic variation in human PRL gene has also been associated with breast cancer risk, specific clinicopathological features, and clinical outcome of the disease.^{5,20,28,34,35,56,64} However, recently contradictory data were reported, raising some doubts regarding the role of PRL in human breast cancer development.^{3,14,24,30,56}

In bitches, different studies have reinforced the role of PRL in mammary gland carcinogenesis,^{31,33,40,41,51} even though some recent contradictory investigations emerged.⁴ Some authors described higher PRL serum levels in cases of mammary neoplasia compared to controls and associated higher levels of tissue PRL with malignancy, tumor relapse or distant metastasis.^40,41 On the other hand, other authors reported no association between PRL expression in canine mammary tumors (CMTs), and actually documented a decline in PRL receptors expression in malignant tumors compared to the benign counterparts.^4,31,33

Data regarding the influence of canine PRL genetic variation in CMTs is largely unknown. In a recent study, our group did not find a relationship between PRL genetic profile and the risk of development of mammary tumors.¹⁰ To date, the influence of PRL genetic profile on the clinicopathological features and progression of CMTs has not been assessed. In this context, the aim of the present study was to investigate the association between single nucleotide polymorphism (SNP) rs23932236 in canine PRL gene and clinicopathological features, clinical progression, and survival of CMTs.

Materials and Methods

The study was conducted by enrolling 206 female dogs with histologically confirmed spontaneous mammary tumors. All animals were treated with radical unilateral and/or partial mastectomy. Informed consent was obtained from owners of animals that participated in this study including consent for surgery with curative intents, as well as for the use of the material for research purposes. Euthanasia, required by the owner or proposed by the veterinary clinician, was performed only in terminal stage of the disease using pentobarbital. This protocol was approved by the Ethics Committee of the Institute of Biomedical Sciences Abel Salazar, ICBAS–UP, University of Porto (P151/2016).

After surgery, mammary specimens were immediately fixed in a 10% buffered formalin solution and routinely processed for histopathological examination. For each case, clinicopathological features including age at the time of the diagnosis, tumor number, and size (corresponding to the largest diameter measured by a pathologist [ACS] during trimming) were recorded. The histological diagnosis was established by consensus of 3 pathologists (ACS, MS, and PDP) using the criteria of Goldschmidt et al (2011).³² The growth pattern was evaluated in each malignant tumor and classified as expansive (cohesive and well-defined mass compressing the adjacent tissues) or infiltrative/invasive (less cohesive, indistinct borders with the surrounding tissues, and lymphatic or blood vessel invasion). In the subgroup of animals with multiple malignant tumors, a reference lesion was assigned for the statistical study based on peritumoral vascular invasion (primary criterion), highest nuclear pleomorphism (secondary criterion), or largest diameter (tertiary criterion).^8,46 Histological grading was assigned by consensus of the same 3 pathologists that diagnosed the tumors using the criteria of the Nottingham Histological Grading Method.²¹ A veterinary adaptation of the human Nottingham Prognostic Index (vet-NPI) was also computed.⁴⁶ Vet-NPI was computed as [tumor size (cm) × 0.2] + NHG (1, 2, or 3, respectively, for grades I, II, and III) + evidence of vascular invasion/regional lymph node metastases (1 or 2 if absent or present, respectively)].

Follow-up data were obtained by consulting the medical records and by contact with the referring veterinarian. Disease-specific overall survival (OS) was calculated from the time of diagnosis to the date of the animal’s death/euthanasia due to the neoplastic disease. Animals that died or were euthanized for unrelated causes and those that were lost to follow-up were censored, respectively, at the time of death and at the date of their last clinical examination. Euthanasia was performed only in terminal stages of the disease. Necropsy examination was performed upon the owner consent.

Genomic DNA was extracted from peripheral blood samples (obtained by standard venipuncture) using High Pure PCR Template preparation kit (Roche). The DNA quality was evaluated by measuring the optical density and the quantity was assessed employing the NanoDrop 1000 Spectrophotometer using a full spectrum of 220 nm to 750 nm (Thermo Fisher Scientific). Only samples with a 260/280 and 260/230 OD ratio of DNA with at least 1.7 to 2 were included in the study. A minimal of 20 to 30 µl with a concentration of 15 ng/µl of DNA was used to perform SNP genotyping. SNP genotyping was performed using MassARRAY iPLEX Gold Technology at the Unidade de Genómica/Serviço de Genotipagem do Instituto Gulbenkian de Ciência (Lisbon, Portugal). This technology for SNP genotyping consists of an initial PCR reaction, followed by multiplexed primer extension (using mass-modified dideoxynucleotide terminators of an oligonucleotide primer), which anneals immediately upstream of the polymorphic site of interest. Additionally, the MALDI-TOF (matrix-assisted laser desorption/ionization–time of flight) mass spectrometry allows the recognition of the SNP allele by the different mass of the extended primer.^22,37

The studied SNP rs23932236 in PRL canine gene (Ensemble database) located in chromosome 35 (primer sequence: 5′- ACG TTG GAT GGG TTC TTA ATG ATC CGT CCC -3′) corresponds to a 3′UTR (untranslated region) variant (Fig. 1).

Figure 1.

Schematic illustration of the SNP in the 3′ sequence of the PRL gene in chromosome 35. The position of the rs23932236 SNP is represented by the red line.

Statistical analysis of data was performed using the computer software SPSS for Windows (version 26). Chi-square analysis (or Fisher’s exact test, when appropriated) was used to evaluate the significance of the relationship between PRL SNP and the categorical variables. For statistical purposes and based on data from previous survival studies, malignant CMTs were divided according to different levels of aggressiveness.^8,13,42

The survival analyses were performed in cases with at least one malignant tumor for which follow-up data were available. Disease-specific survival curve was computed using Kaplan-Meier product-limit estimates method and the log-rank (Mantel-Cox) test. Cox proportional hazard regression models were used to evaluate the prognostic role of the studied SNP and clinicopathological variables in univariate analyses using the 95% confidence interval. As to the histological subtypes, only the categories with 8 or more cases were included in the statistical models. A 5% level was considered to define statistical significance.

Results

This study included 206 bitches with a mean age of 10.1 years old (range, 7–18 years old). For the population included in this study, the frequency of SNP rs23932236 was 34.5% for GG, 47.1% for GC, and 18.4% for CC (Table 1).

Table 1.

Genotypic and Allele Frequencies of the Single Nucleotide Polymorphism rs23932236 in 206 Dogs With Mammary Neoplasia.

		Frequency (n)	Percentage
Genotypes	CC	38	18.4
	GG	71	34.5
	GC	97	47.1
	Total	206	100.0

Only benign tumors were diagnosed in 73 female dogs (mean age 9.68 years), while 133 female dogs presented at least one malignant tumor (mean age 10.4 years). Table 2 and Supplemental Table S1 present the histological subtypes of benign and malignant tumors diagnosed according to Goldschmidt et al (2011). Mixed benign and complex carcinomas were the most frequently diagnosed benign and malignant subtypes, representing 45.2% and 15.8% of the tumors, respectively. Multiple tumors were diagnosed in 65.5% of the cases. The mean tumor size for benign tumors was 2.1 cm (range 0.3 to 8.5 cm diameter) and for malignant tumors 3.7 cm (range 0.3 to 16.5 cm diameter).

Table 2.

Histological Subtypes of Benign and Malignant Mammary Tumors Diagnosed in 206 Female Dogs.

Histological subtype^a	n
Simple adenoma	11
Complex adenoma	25
Basaloid adenoma	4
Mixed benign tumor	33
Carcinoma—anaplastic	1
Carcinoma—in situ	4
Carcinoma—tubulopapillary	17
Carcinoma—tubular	4
Carcinoma—cribriform	2
Carcinoma—cystic papillary	2
Carcinoma—micropapillary	1
Carcinoma—solid	12
Comedocarcinoma	10
Carcinoma—complex in adenoma/mixed tumor	8
Carcinoma—complex	21
Carcinoma and malignant myoepithelioma	2
Carcinoma—mixed	10
Carcinoma intraductal papillary	4
Squamous cell carcinoma	3
Adenosquamous carcinoma	9
Carcinoma—mucinous	3
Carcinoma—spindle	2
Carcinosarcoma	9
Osteosarcoma	2
Other sarcomas	7

^a Histological classification performed according to Goldschmidt et al (2011).

Based on the Nottingham Histological Grading Method 36/106 (34.0%) carcinomas were grade I, 47/106 (44.3%) were grade II, and 23/106 (21.7%) were grade III. Vascular invasion (assessed in 130 malignant cases) and lymph node metastasis (lymph nodes were collected during the macroscopic examination of the mammary specimens in 116 cases) were observed in 22/130 (16.9%) and in 31/116 (26.7%) of cases, respectively. Two-year follow-up data were available for 116 dogs with at least one malignant tumor. Of those, 57/116 (49.1%) were alive at the end of the follow-up period, while 31/116 (26.7%) died due to progression of the disease. From these 31 animals, 11 were necropsied upon the owner’s authorization; necropsy and microscopic findings confirmed disseminated metastatic disease in all those cases. Animals lost to follow-up and animals that died from causes not related to the mammary neoplasia (n = 28/116; 24.1%) were censored.

Table 3 presents results regarding the association between SNP rs23932236 and clinicopathological parameters. Carriers of the variant allele for SNP rs23932236 (ie, genotypes CC and GC) developed larger malignant tumors (>3 cm of diameter) than wildtype animals (P = .036), mostly with an infiltrative or invasive growth pattern (P = .010). Furthermore, a significant association was found between this genotype and vascular invasion (P = .006) and lymph node metastasis (P = .004). In fact, most of the cases with microscopic evidence of vascular invasion (90.9%) and lymph node metastasis (87.1%) had the variant allele. No significant associations were established between rs23932236 and the age of the animals, number of tumors, histological classification (regrouped), NGH histological grade and its corresponding parameters, or vet-NPI.

Table 3.

Association Between SNP rs23932236 in PRL gene (71 GG, 135 CC or CG) With Clinicopathological Variables in 206 Female Dogs With Mammary Tumors.

Independent variables	Genotype (n = number of cases)		P
Independent variables	CC/CG, n (%)	GG, n (%)	P
Age
≤10	80 (65.6)	42 (34.4)
>10	52 (66.7)	26 (33.3)	NS
Reproductive status
Not neutered	101 (65.2)	54 (34.8)
Neutered	19 (61.3)	12 (38.7)	NS
Number of tumors
Single	47 (66.2)	24 (33.8)
Multiple	88 (65.2)	47 (34.8)	NS
Tumor size
≤3 cm	73 (58.4)	41 (60.3)
>3 cm	52 (41.6)	27 (39.7)	NS
Tumor size (only malignant)
≤3 cm	36 (42.9)	28 (62.2)
>3 cm	48 (57.1)	17 (37.8)	0.036
Biological behavior
Benign	49 (36.3)	24 (33.8)
Malignant	86 (63.7)	47 (66.2)	NS
Mode of growth pattern
Expansive	29 (33.7)	22 (46.8)
Infiltrative	27 (31.4)	20 (42.6)
Invasive	30 (34.9)	5 (10.6)	.010
NHG parameters scores
Tubule formation
Score 1	18 (25.7)	7 (19.4)
Score 2	29 (41.4)	17 (47.2)
Score 3	23 (32.9)	12 (33.3)	NS
Nuclear pleomorphism
Score 1	6 (8.6)	4 (11.1)
Score 2	44 (62.9)	22 (61.1)
Score 3	20 (28.6)	10 (27.8)	NS
Mitotic index
Score 1	26 (37.1)	17 (47.2)
Score 2	22 (31.4)	6 (16.7)
Score 3	22 (31.4)	13 (36.1)	NS
NHG
Grade I	22 (31.4)	14 (38.9)
Grade II	33 (47.1)	14 (38.9)
Grade III	15 (21.4)	8 (22.2)	NS
Vet-NPI
≤4.0	35 (51.5)	25 (69.4)
>4.0	33 (48.5)	11 (30.6)	NS
Vascular invasion
No	65 (76.5)	43 (95.6)
Yes	20 (23.5)	2 (4.4)	0.006
Lymph node metastases
No	50 (64.9)	35 (89.7)
Yes	27 (35.1)	4 (10.3)	0.004

Abbreviations: SNP, single nucleotide polymorphism; NHG, Nottingham Histological Grade; vet-NPI, veterinary adapted Nottingham Prognostic Index.

The rs23932236 genotype was significantly associated with overall survival (Fig. 2). Carriers of the variant allele (ie, genotypes CC and GC) had a mean OS of 18.7 months (95% confidence interval [CI] 17.0–20.5 months) while the wild-type population (ie, genotype GG) had a mean OS of 22.7 months (95% CI 21.0–24.4 months; P = .004; Fig. 2). By Cox univariable regression analysis, the risk of death related to the neoplastic disease was 4 times higher (odds ratio = 4.11, 95% CI 1.43–11.76; P = .008) in cases with the genetic variant compared to the wild-type.

Figure 2.

Kaplan-Meier plots of the estimate of the disease-specific overall survival for female dogs with malignant mammary tumors that have a single nucleotide polymorphism (rs23932236) of the prolactin gene (CC or CG genotype; dotted line) compared to the wildtype (GC genotype; solid line). Censoring is indicated by the + symbol.

Discussion

SNPs affect the risk, disease expression patterns, and prognosis of several types of human cancers including breast cancer and this may improve the development of personalized medicine.^{26,29,38,53,55,57} In dogs, the genetic profile (including SNPs) have been associated with the risk, clinicopathological features, biological behavior, and prognosis of CMTs.^{6,7,9

–13,18,19,45} The present study aimed to assess the influence of PRL gene SNP rs23932236 on CMTs features and outcome.

The rs23932236 is SNP in the 3′UTR (untranslated region) of the PRL gene. Although this flanking sequence is not translated into protein (and thus the SNP does not affect the protein sequence), it may affect gene expression⁵² such as by effects on RNA stability, mRNA translation, and access to regulatory elements such as miRNA and RNA-binding proteins. These functional changes interfere with multiple molecular pathways, and may thus contribute to the development and/or modulation of the phenotype, onset, and outcome of diseases.^47,52

In a recent case-control study, we did not find a relation between the SNP rs23932236 and the development of CMTs.¹⁰ Nevertheless, the present results demonstrated that, within the group of female dogs developing malignant tumors, cases with this SNP had shorter survival, and the SNP was significantly associated with other indicators of poor prognostic factors including larger tumor size, infiltrative/invasive growth, vascular invasion, lymph node metastasis.

The association between SNP rs23932236 in canine PRL gene and well-known poor prognostic features of CMTs, specifically large tumor size, infiltrative/invasive growth, vascular invasion, and lymph-node metastasis, was further substantiated by the survival analysis. Accordingly, variant allele carriers exhibited a significantly shorter OS and a 4 times higher risk of death related to neoplastic disease than the wild-type population. These results may allow the identification of a subgroup of cases that tend to develop aggressive disease and thus must be subject to rigorous surveillance protocols and clinical monitoring.

PRL has pro-proliferative and anti-apoptotic effects on the mammary gland.¹⁷ It is speculated that canine genetic variants such as SNP rs23932236 might influence the anti-apoptotic effects of PRL on mammary tissues contributing to their amplification, thus perhaps resulting in increased tumor growth and a higher probability of larger tumor size.³⁹ PRL has also been implicated in enhanced motility of human breast cancer cells.¹⁷ Furthermore, PRL may affect tumor neovascularization^15,16,43 by promoting release of pro-angiogenic factors by leukocytes and epithelial cells, enhancing intussusceptive angiogenesis (splitting angiogenesis) by increasing vessel density and tortuosity, inducing endothelial cell migration, and promoting tube formation of endothelial cells on in vitro devices.⁴³ Enhanced cell motility and invasiveness, combined with increased angiogenesis, favors vascular invasion by neoplastic cells and development of metastasis. These data find parallel with studies in human breast cancer that reported an association between genetic variation attributed to SNPs in PRL gene and the development of metastasis.³⁴ Further molecular and functional studies are needed in order to understand the mechanisms by which the SNP rs23932236 affects the progression and outcome of canine mammary neoplasia, and to evaluate the role of genetic epistasis and the hormonal environment, namely the interplay between PRL, estrogen, progesterone and PRL receptor genes.

In conclusion, genetic variation in the canine PRL gene was associated with the phenotypical features, progression, and outcome of malignant CMTs. The presence of the SNP rs23932236 identified a subgroup of animals prone to develop aggressive mammary tumors with poor survival that may thus benefit from the implementation of specific clinical monitoring protocols.

Supplemental Material

Supplemental Material, sj-pdf-1-vet-10.1177_03009858211022705 - Single Nucleotide Polymorphism in Prolactin Gene Is Associated With Clinical Aggressiveness and Outcome of Canine Mammary Malignant Tumors

Supplemental Material, sj-pdf-1-vet-10.1177_03009858211022705 for Single Nucleotide Polymorphism in Prolactin Gene Is Associated With Clinical Aggressiveness and Outcome of Canine Mammary Malignant Tumors by Ana Canadas-Sousa, Marta Santos, Rui Medeiros and Patrícia Dias-Pereira in Veterinary Pathology

Footnotes

Acknowledgements

The authors would like to thank Ricardo Pinto for his contribution for the gene map construction. We are also thankful to Veterinary Pathology Laboratory and Immunogenetic Laboratory (ICBAS, University of Porto) staff for technical support; to the clinicians Miguel França, Cristina Pereira, Jorge Ribeiro, Flora Tinoco, Raquel Vilaça, Maria João Silva, and Hugo Vilhena; to Helena Frias of Vila Nova de Gaia Kennel and Aanifeira animal association; to the animals and tutors involved in the study.

Author Contributions

ACS helped conceive the study and its design, collected the control and cases blood samples, carried out the DNA isolation, performed CMTs analysis, and drafted the manuscript. MS contributed to conceive the study and its design, performed CMTs analysis, and revised the manuscript. RM contributed to the SNP and haplotype association analyses, statistical analysis, and revised the manuscript. PDP conceived the study and its design, performed CMTs analysis, and drafted the manuscript. All authors read and approved the final manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Ana Canadas-Sousa

Marta Santos

Supplemental Material

Supplemental material for this article is available online.

References

Arendt

Rugowski

Grafwallner-Huseth

, et al. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res. 2011;13(1):R11.

Bachelot

Binart

. Reproductive role of prolactin. Reproduction. 2007;133(2):361–369.

Bignami

Lissoni

Brivio

, et al. The favorable prognostic significance of surgery-induced hyperprolactinemia in node-positive breast cancer patients: ten-year disease-free survival results. Int J Biol Markers. 2005;20(1):60–64.

Bohrer

Löhr

Kutzler

. Prolactin and growth hormone immunoactivity in canine mammary adenomas and adenocarcinomas. Reprod Domest Anim. 2017;52(Suppl 2):293–297.

Booms

Coetzee

Pierce

. MCF-7 as a model for functional analysis of breast cancer risk variants. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1735–1745.

Borge

Borresen-Dale

Lingaas

. Identification of genetic variation in 11 candidate genes of canine mammary tumour. Vet Comp Oncol. 2011;9(4):241–250.

Borge

Melin

Rivera

, et al. The ESR1 gene is associated with risk for canine mammary tumours. BMC Vet Res. 2013;9:69.

Canadas

Franca

Pereira

, et al. Canine mammary tumors: comparison of classification and grading methods in a survival study. Vet Pathol. 2019;56(2):208–219.

Canadas

Santos

Medeiros

, et al. Influence of E-cadherin genetic variation in canine mammary tumour risk, clinicopathological features and prognosis. Vet Comp Oncol. 2019;17(4):489–496.

10.

Canadas

Santos

Nogueira

, et al. Canine mammary tumor risk is associated with polymorphisms in RAD51 and STK11 genes. J Vet Diagn Invest. 2018;30(5):733–738.

11.

Canadas

Santos

Pinto

, et al. Catechol-o-methyltransferase genotypes are associated with progression and biological behaviour of canine mammary tumours. Vet Comp Oncol. 2018;16(4):664–669.

12.

Canadas-Sousa

Santos

Leal

, et al. Estrogen receptors genotypes and canine mammary neoplasia. BMC Vet Res. 2019;15(1):325.

13.

Canadas-Sousa

Santos

Medeiros

, et al. Single nucleotide polymorphisms influence histological type and grade of canine malignant mammary tumours. J Comp Pathol. 2019;172:72–79.

14.

Chakhtoura

Laki

Bernadet

, et al. Gain-of-function prolactin receptor variants are not associated with breast cancer and multiple fibroadenoma risk. J Clin Endocrinol Metab. 2016;101(11):4449–4460.

15.

Clapp

Thebault

Macotela

, et al. Regulation of blood vessels by prolactin and vasoinhibins. Adv Exp Med Biol. 2015;846:83–95.

16.

Clapp

Thebault

de la Escalera

. Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland. J Mammary Gland Biol Neoplasia. 2008;13(1):55–67.

17.

Clevenger

Furth

Hankinson

, et al. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24(1):1–27.

18.

Dias Pereira

Lopes

Matos

, et al. Estrogens metabolism associated with polymorphisms: influence of COMT G482a genotype on age at onset of canine mammary tumors. Vet Pathol. 2008;45(2):124–130.

19.

Dias Pereira

Lopes

Matos

, et al. Influence of catechol-O-methyltransferase (COMT) genotypes on the prognosis of canine mammary tumors. Vet Pathol. 2009;46(6):1270–1274.

20.

Ellingjord-Dale

Lee

Couto

, et al. Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users. Breast Cancer Res. 2012;14(5):R135.

21.

Elston

Ellis

. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–410.

22.

Gabriel

Ziaugra

Tabbaa

. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009;Chapter 2 :Unit 2.12.

23.

Gabrielson

Ubhayasekera

, et al. Inclusion of plasma prolactin levels in current risk prediction models of premenopausal and postmenopausal breast cancer. JNCI Cancer Spectr. 2018;2(4):pky055.

24.

Hachim

Shams

Lebrun

, et al. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome. Hum Pathol. 2016;53:142–152.

25.

Harris

Stanford

Oakes

, et al. Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med. 2004;36(6):414–425.

26.

Howe

Miron-Shatz

Hanoch

, et al. Personalized medicine through SNP testing for breast cancer risk: clinical implementation. J Genet Couns. 2015;24(5):744–751.

27.

Hüsing

Fortner

Kühn

, et al. Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: results from the EPIC cohort. Clin Cancer Res. 2017;23(15):4181–4189.

28.

Lee

Haiman

Burtt

, et al. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med Genet. 2007;8:72.

29.

Liu

Wang

Zhang

, et al. Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. Hum Genomics. 2015;9(1):2.

30.

López-Ozuna

Hachim

, et al. Prolactin pro-differentiation pathway in triple negative breast cancer: impact on prognosis and potential therapy. Sci Rep. 2016;6:30934.

31.

Michel

Feldmann

Kowalewski

, et al. Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas. BMC Vet Res. 2012;8:72.

32.

Goldschmidt

Peña

Rasotto

Zappulli

. Classification and Grading of Canine Mammary Tumors. Vet Pathol. 2011;48(1):117–131.

33.

Mohr

Lüder Ripoli

Hammer

, et al. Hormone receptor expression analyses in neoplastic and non-neoplastic canine mammary tissue by a bead based multiplex branched DNA assay: a gene expression study in fresh frozen and formalin-fixed, paraffin-embedded samples. PLoS One. 2016;11(9):e0163311.

34.

Mong

Kuo

Liu

, et al. Association of gene polymorphisms in prolactin and its receptor with breast cancer risk in Taiwanese women. Mol Biol Rep. 2011;38(7):4629–4636.

35.

Nyante

Faupel-Badger

Sherman

, et al. Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland. Breast Cancer Res. 2011;13(2):R42.

36.

O’Leary

Shea

Salituro

, et al. Prolactin alters the mammary epithelial hierarchy, increasing progenitors and facilitating ovarian steroid action. Stem Cell Reports. 2017;9(4):1167–1179.

37.

Oeth

del Mistro

Marnellos

, et al. Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY). Methods Mol Biol. 2009;578:307–343.

38.

Offit

. Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130(1):3–14.

39.

Provencher

Diorio

Hogue

, et al.

Does breast cancer tumor size really matter that much?

The Breast. 2012;21(5):682–685.

40.

Queiroga

Pérez-Alenza

González Gil

, et al. Clinical and prognostic implications of serum and tissue prolactin levels in canine mammary tumours. Vet Rec. 2014;175(16):403.

41.

Queiroga

Perez-Alenza

Silvan

, et al. Role of steroid hormones and prolactin in canine mammary cancer. J Steroid Biochem Mol Biol. 2005;94(1-3):181–187.

42.

Rasotto

Berlato

Goldschmidt

, et al. Prognostic significance of canine mammary tumor histologic subtypes: an observational cohort study of 229 cases. Vet Pathol. 2017;54(4):571–578.

43.

Reuwer

Nowak-Sliwinska

Mans

, et al.

Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?

J Cell Mol Med. 2012;16(9):2035–2048.

44.

Reynolds

Montone

Powell

, et al. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology. 1997;138(12):5555–5560.

45.

Rivera

Melin

Biagi

, et al. Mammary tumor development in dogs is associated with BRCA1 and BRCA2. Cancer Res. 2009;69(22):8770–8774.

46.

Santos

Correia-Gomes

Marcos

, et al. Value of the Nottingham histological grading parameters and Nottingham prognostic index in canine mammary carcinoma. Anticancer Res. 2015;35(7):4219–4227.

47.

Schwerk

Savan

. Translating the untranslated region. J Immunol. 2015;195(7):2963–2971.

48.

Sethi

Chanukya

Nagesh

. Prolactin and cancer: has the orphan finally found a home? Indian J Endocrinol Metab. 2012;16(Suppl 2):S195–S198.

49.

Shemanko

. Prolactin receptor in breast cancer: marker for metastatic risk. J Mol Endocrinol. 2016;57(4):R153–R165.

50.

Smithline

Sherman

Kolodny

. Prolactin and breast carcinoma. N Engl J Med. 1975;292(15):784–792.

51.

Spoerri

Guscetti

Hartnack

, et al. Endocrine control of canine mammary neoplasms: serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors. BMC Vet Res. 2015;11:235.

52.

Steri

Idda

Whalen

, et al. Genetic variants in mRNA untranslated regions. Wiley Interdiscip Rev RNA. 2018;9(4):e1474.

53.

Stover

Wagle

. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep. 2015;17(4):15.

54.

Touraine

Martini

Zafrani

, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab. 1998;83(2):667–674.

55.

Tsuchida

Rothman

McDonald

, et al. Clinical target sequencing for precision medicine of breast cancer. Int J Clin Oncol. 2019;24(2):131–140.

56.

Vaclavicek

Hemminki

Bartram

, et al. Association of prolactin and its receptor gene regions with familial breast cancer. J Clin Endocrinol Metab. 2006;91(4):1513–1519.

57.

van’t Veer

Bernards

. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452(7187):564–570.

58.

Wang

Chai

, et al. Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep. 2016;6:25998.

59.

Weaver

Hernandez

. Autocrine-paracrine regulation of the mammary gland. J Dairy Sci. 2016;99(1):842–853.

60.

Welsch

Brown

Goodrich-Smith

, et al. Inhibition of mammary tumorigenesis in carcinogen-treated Lewis rats by suppression of prolactin secretion. J Natl Cancer Inst. 1979;63(5):1211–1214.

61.

Welsch

Nagasawa

. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 1977;37(4):951–963.

62.

Wennbo

Gebre-Medhin

Gritli-Linde

, et al. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest. 1997;100(11):2744–2751.

63.

Yang

Wan

, et al. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. J Clin Endocrinol Metab. 2011; 96(10):E1619–E1629.

64.

Yoshimoto

Nishiyama

Toyama

, et al. Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. Cancer Sci. 2011;102(11):2065–2072.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB